Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Challenges and Opportunities for Generic Medicines Development Outlook for European Industry in current
Economic Recession
Gudbjorg Edda Eggertsdottir December 6, 2012
Watson acquires Actavis
• Acquisition value EUR 4.25 billion (USD 5.5 billion)
• Acquisition closed 31 Oct 2012
• Creates 3rd largest global generics company
• ~$8.0 billion projected 2012 pro forma combined revenue
• 17,000 employees
• Strengthened commercial position with footprint in 60+ countries
• 30+ manufacturing facilities; ~44 billion unit capacity
• 12 global R&D centers
Two powerful, profitable and rapidly growing companies into one exceptional global business
Global Powerhouse
Our global marketplace
60/+ countries
5 billion potential customers
Top 3 in 12 markets
Top 5 in 16 markets
Watson Will Continue to Grow
• Well-Defined, Balanced Growth Strategy • Global Generics
• Global Brands and Biosimilars
• Anda Distribution
• Supported by Leading Global Supply Chain
• Substantial Investment in Internal Growth • Significant investment in internal R&D
• Investments in people/resources to support marketing and sales growth
• Financial Strength to Drive External Growth • Expanding market/geographic access through Actavis
acquisition
Key role of generic and
biosimilar medicines
Affordability Accessibility Availability
Generic
Medicines
• Approximately $30bn can be saved globally by improving
suboptimal use of generics*
• Japan has the biggest opportunity, followed by Cyprus
*IIHI Ministers Report 17.09.12 from IMS Institute for Healthcare Informatics
Opportunities
• Global generic spending is growing by over 10% a
year to reach around $415 billion by 2016*
• Fastest growth in pharmerging markets
• Europe‘s share in growth drastically reduced
• New emerging markets with high purchasing
power (Russia, China, Middle East, Africa)
• Demographic changes (ageing and growing
populations) both in Europe and globally
• Patent expiries in developed countries
*IMS Market Prognosis 2012
Challenges
• Increasing regulatory requirements to manage more
complex operations • New pharmacovigilance requirements
• Anti-counterfeit measures – implementation of FM directive
• Unique identifier
• API controls
• Management of continuity of supply
• Increasing competition from countries outside Europe • Lack of level playing field
• Market access barriers and delays as identified in the EC
Sector Inquiry
• Strong price pressure in the EU
Influence of recession on pharma market
Pharmaceutical growth trend in Europe is a major concern Cost-containment and austerity measures a key driver
Europe
2001-2005
CAGR
8%
2006-2010
CAGR
6%
2011-2015
CAGR
1-4%
Regions
Source: IMS Market Prognosis 2011
Top 5: 7% 5% 0-3%
Other West: 8% 4% (-1)-2%
East: 13% 11% 6-9%
Payers in Europe have implemented cost
containment measures targeting
pharmaceutical supply and/or demand
Supply side Demand side
All reducing growth
• Reference pricing
• Volume controls
• Mandatory price cuts
• Rebates and clawbacks
• Faster to implement
• Widely seen in crisis struck (IMF) countries
• Promotion of generics
• Prescribing budgets
• Patient co-payment
• Risk sharing agreements
• Slower to implement
• Long-term sustainability
• Technology often required
69%
21%
10%
Brand Generic Other
Generic penetration will continue to grow
based on patent expiries and economic
pressures
Source: IMS Market Prognosis, Sep 2011
Sales by Segment
52% 40%
8%
63%
28%
9%
$610Bn $876Bn
$1,120Bn
2010 2005 2015
Biosimilar Products in the 7MM Despite impressive growth biosimilars still account for very small
portion of biologics sales (~3% of the relevant drug classes in terms of US$ in 2011)
0
50
100
150
200
250
300
350
400
2007 2008 2009 2010 2011
US$m
m epoetin theta
epoetin zeta
epoetin alfa
filgrastim
somatropin
~107% CAGR %, 2007-11
$20mm
$76mm
$144mm
$256mm
$365mm
Source: IMS Health, MIDAS, MAT Q4 2011; Actavis research
7MM – US, Japan, France, Germany, Italy, Spain and UK
Regulatory hurdles
Key hurdle: lack of right for EU
companies to manufacture during
SPC
• Global competition from
key emerging markets (India,
South Korea, Russia, China,
Brazil)
• Lack of provision for
advanced manufacturing
during SPC in Europe
Emerging
Markets
SPC
EU generics
industry
Key hurdle: Major increase in costs
due to the Falsified Medicines
Directive
• The implementation
costs of possible new
anti-falsification
technologies for the
EU generic industry
could reach € 1
billion.
WARNING
€ 1 billion
Key hurdle: Possible shortages
due to API supply problems
API sourced from outside
the EU 75%
API sourced from the EU
25%
API Supply
• EU is implementing a new requirement for API imported into the EU – written
confirmation of GMP status
• Key supplying countries must get prepared (India, China, etc.)
How can we strengthen
the industry?
Europe 2020 Barroso commission II
• Three mutually reinforcing
priorities:
I. Smart growth: developing an
economy based on knowledge and
innovation.
II. Sustainable growth: promoting a
more resource efficient, greener
and more competitive economy.
III. Inclusive growth: fostering a
high-employment economy
delivering social and territorial
cohesion.
Export Loss of EU Generic and
Biosimilar Medicines Industry
Period of market loss
to EU companies
Date of international
competition
20 year patent + Up to 5 year SPC
Leading countries in number of
Canidates for biosimilars
European Generic Medicines Industry:
Major Contributor to Employment and
Development
European countries with
generic medicines R&D and
manufacturing
European countries with
generic medicines
manufacturing
Source: EGA
Internal survey
2010
Updated 2010.10
EU2020 Industrial Policy – priorities
for generic and biosimilar medicines
industry
• Creating a sustainable internal market for generic and biosimilar
medicines
• Creating sustainable pricing and reimbursement
• Tax exemptions and funds for generic R&D
• Tax initiatives for manufacturing jobs
• Fostering market access in third countries
• Advanced manufacturing for export
• Eradication of non-tariff barriers in 3rd countries
• Improved mutual recognition of API inspections
• Better regulation
• Harmonisation of quality standards to ICH Standards
• Establishing global development for biosimiliar medicines
EU-US Task force
• EGA and GPhA jointly support setting up a High Level Working
Group on Growth and Jobs to create opportunities for the
European and American industries in the globalised economy.
• EGA and GPhA have put forward practical priority measures for our
industry:
• global development and international harmonisation of data
requirements for approval of biosimilar medicinal products
• single development programme and international harmonisation of
data requirements for approval of generic medicinal products
• mutual recognition of compliance inspections
• not mismatching the EU and the US IP rights systems
• advanced manufacturing provision
Global development of
biosimilars
• We are very close to a breakthrough! • Europe is now willing to embrace the concept of
a global reference product for biosimilars
• Also US FDA, and Canadian authorities have
indicated willingness to support global
development.
• Generics remain key in containing costs post
patent expiry • Generic penetration continues to vary based on
specific country drivers
• Massive savings can still be made globally by
optimizing use of generics
• Price reductions continue to exert pressure on
generics • Sustainable price & reimbursement systems
need to be implemented
• Reference pricing systems need to be improved
• Regulatory requirements need to fit the
purpose • If it isn’t a problem, don’t fix it!
• International harmonization is key
Final comments
Thank you!